An Enolase Inhibitor for the Targeted Treatment of ENO1-Deleted Cancers

Inhibiting glycolysis remains an aspirational approach for the treatment of cancer. We previously identified a subset of cancers harboring homozygous deletion of the glycolytic enzyme Enolase (ENO1) with exceptional sensitivity to inhibition of its redundant paralogue, ENO2, through a therapeutic st...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yu-Hsi, Satani, Nikunj, Hammoudi, Naima, Yan, Victoria C., Barekatain, Yasaman, Khadka, Sunada, Ackroyd, Jeffrey J., Georgiou, Dimitra K., Pham, Cong-Dat, Arthur, Kenisha, Maxwell, David, Peng, Zhenghong, Leonard, Paul G., Czako, Barbara, Pisaneschi, Federica, Mandal, Pijus, Sun, Yuting, Zielinski, Rafal, Pando, Susana Castro, Wang, Xiaobo, Tran, Theresa, Xu, Quanyu, Wu, Qi, Jiang, Yongying, Kang, Zhijun, Asara, John M., Priebe, Waldemar, Bornmann, William, Marszalek, Joseph R., DePinho, Ronald A., Muller, Florian L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744354/
https://www.ncbi.nlm.nih.gov/pubmed/33230295
http://dx.doi.org/10.1038/s42255-020-00313-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744354/
https://www.ncbi.nlm.nih.gov/pubmed/33230295
http://dx.doi.org/10.1038/s42255-020-00313-3

Ejemplares similares